Dexcel Company Profile
✉ Email this page to a colleague
What is the competitive landscape for DEXCEL
DEXCEL has seventeen approved drugs.
There are seven US patents protecting DEXCEL drugs. There is one tentative approval on DEXCEL drugs.
There are thirteen patent family members on DEXCEL drugs in six countries and fifty-nine supplementary protection certificates in sixteen countries.
Summary for Dexcel
| International Patents: | 13 |
| US Patents: | 7 |
| Tradenames: | 14 |
| Ingredients: | 14 |
| NDAs: | 17 |
| Patent Litigation for Dexcel: | See patent lawsuits for Dexcel |
Drugs and US Patents for Dexcel
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dexcel | NINTEDANIB ESYLATE | nintedanib esylate | CAPSULE;ORAL | 219819-001 | Apr 2, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Dexcel | LANSOPRAZOLE | lansoprazole | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | 208025-001 | Jun 7, 2016 | OTC | No | No | 11,986,554 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Dexcel | DONEPEZIL HYDROCHLORIDE | donepezil hydrochloride | TABLET;ORAL | 203713-001 | Feb 19, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Dexcel | VENLAFAXINE HYDROCHLORIDE | venlafaxine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209193-002 | Oct 31, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Dexcel Ltd | ISOSORBIDE MONONITRATE | isosorbide mononitrate | TABLET, EXTENDED RELEASE;ORAL | 075522-002 | Sep 20, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Dexcel
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Dexcel Pharma | OMEPRAZOLE | omeprazole | TABLET, DELAYED RELEASE;ORAL | 022032-001 | Dec 4, 2007 | 9,023,391 | ⤷ Start Trial |
| Dexcel Pharma | PERIOCHIP | chlorhexidine gluconate | TABLET;DENTAL | 020774-001 | May 15, 1998 | 5,023,082 | ⤷ Start Trial |
| Dexcel Pharma | PERIOCHIP | chlorhexidine gluconate | TABLET;DENTAL | 020774-001 | May 15, 1998 | 5,002,769 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for DEXCEL drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
International Patents for Dexcel Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2017285390 | ⤷ Start Trial |
| European Patent Office | 3288556 | ⤷ Start Trial |
| Israel | 255048 | ⤷ Start Trial |
| European Patent Office | 3932396 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2019123453 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Dexcel Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1830843 | 132016000021977 | Italy | ⤷ Start Trial | PRODUCT NAME: NINTEDANIB, SUOI TAUTOMERI, O LORO MISCELE O I SUOI SALI, IN PARTICOLARE ESILATO DI NINTEDANIB(OFEV); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/979, 20150119 |
| 0124495 | SPC/GB01/006 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727 |
| 1224170 | SPC/GB15/018 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: NINTEDANIB*, THE TAUTOMERS AND THE SALTS THEREOF, IN PARTICULAR NINTEDANIB AND PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF, SPECIFICALLY NINTEDANIB ESILATE. *NINTEDANIB IS 3-Z-(1-(4-N-((4-METHYL-PIPERAZIN-1-YL)-METHYLCARBONYL)-N-METHYL-AMINO)-A; REGISTERED: UK EU/1/14/954/001 20141125; UK EU/1/14/954/002 20141125; UK EU/1/14/954/003 20141125; UK EU/1/14/954/004 20141125 |
| 1666481 | 2017/036 | Ireland | ⤷ Start Trial | PRODUCT NAME: TOFACITINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE CITRATE SALT; REGISTRATION NO/DATE: EU/1/17/1178/001 EU/1/17/1178/004 20170322 |
| 0296560 | SPC/GB97/023 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
